Oral Insulin Therapy to Prevent Progression of Immune‐Mediated (Type 1) Diabetes
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
A bstract: Repeated ingestion of insulin has been suggested as an immune tolerization therapy to prevent immune‐mediated (type 1) diabetes. We performed a placebo‐controlled, two‐dose, oral insulin tolerance trial in newly diagnosed (< 2 years) diabetic patients who had required insulin replacement for less than 4 weeks and were found to have cytoplasmic islet cell autoantibodies (ICAs). No oral hypoglycemic agents were permitted during the trial. Endogenous insulin reserves were estimated at six‐month intervals by plasma C‐peptide responses to a mixed meal. Positive ICAs were found in 262 (31%) of the 846 patients screened. Of the 197 who agreed to participate, 187 could be followed for 6 to 36 months. Endogenous insulin retention was dependent upon initial stimulated C‐peptide response, age at diabetes onset, and numbers of specific islet cell autoantibodies found. Oral insulin improved plasma C‐peptide responses in patients diagnosed at ages greater than 20 years, best seen at the low (1 mg/day) over the high (10 mg/day) insulin dose (P= .003 and P= .01, respectively). In patients diagnosed before age 20 years, the 1 mg dose was ineffective, whereas the 10 mg dose actually accelerated C‐peptide loss (P= .003). There were no adverse effects. If confirmed, these findings suggest that diabetic patients over age 20 years with ICA evidence of late‐onset immune‐mediated diabetes should be considered for oral insulin at 1 mg/day to better retain endogenous insulin secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00001 · Cited by 546
Feutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91943-4 · Cited by 448
Vardi, P., Crisa, L., Jackson, R. A., Dumont Herskowitz, R., Wolfsdorf, J. I., Einhorn, D., Linarelli, L., Dolinar, R., Wentworth, S., Brink, S. J., et al. (1991) · Diabetologia · doi:10.1007/bf00500379 · Cited by 122
Maclaren, N., Lan, M., Coutant, R., Schatz, D., Silverstein, J., Muir, A., Clare-Salzer, M., She, J.-X., Malone, J., Crockett, S., et al. (1999) · Journal of Autoimmunity · doi:10.1006/jaut.1999.0281 · Cited by 117
Self-citation
Cited by
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011) · Physiological Reviews · doi:10.1152/physrev.00003.2010 · Cited by 1,022
“This approach has also led to success in T1D patients (87, 120, 133)(Table 3).”
ResultFaria, A. M. C., & Weiner, H. L. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00280.x · Cited by 601
CD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Näntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease
Miller, S. D., Turley, D. M., & Podojil, J. R. (2007) · Nature Reviews Immunology · doi:10.1038/nri2153 · Cited by 290
Metadata
- Authors
- ERGUN‐LONGMIRE, B., MARKER, J., ZEIDLER, A., RAPAPORT, R., RASKIN, P., BODE, B., SCHATZ, D., VARGAS, A., ROGERS, D., SCHWARTZ, S., MALONE, J., KRISCHER, J., & MACLAREN, N. K.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 1029
- Issue
- 1
- Pages
- 260-277
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2009721531
- Cited by
- 65
- References
- 5
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Insulin Therapy to Prevent Progression of Immune‐Mediated (Type 1) Diabetes. https://app.cochat.ai/papers/10.1196/annals.1309.057
- The paper
- ERGUN‐LONGMIRE, B., MARKER, J., ZEIDLER, A., RAPAPORT, R., RASKIN, P., BODE, B., SCHATZ, D., VARGAS, A., ROGERS, D., SCHWARTZ, S., MALONE, J., KRISCHER, J., & MACLAREN, N. K. (2004). Oral Insulin Therapy to Prevent Progression of Immune‐Mediated (Type 1) Diabetes. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1309.057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.